The World's Medicine Cabinet Is Looking for Stronger Foundations
India is a major supplier of generic medicines. What supports its pharma clusters, and what quality and supply-chain challenges lie ahead for manufacturers.
Quality technician in a pharma lab holding a sample vial, bright and clean · Editorial preview.
The World's Medicine Cabinet
India is widely described as a leading supplier of generic medicines, with exports to many countries. [VERIFY: pharma exports reported at above $28 billion; source from the Pharmexcil/commerce ministry release.] The industry sits in clusters: Hyderabad's Genome Valley and pharma parks, Ahmedabad and Vadodara in Gujarat, and Baddi in Himachal Pradesh.
The Upstream Challenge
The structural challenge is upstream. India depends heavily on imports for active pharmaceutical ingredients (APIs) and key starting materials. PLI schemes and bulk-drug parks were designed to build domestic capacity.
For MSME pharma units the priorities are regulatory quality (good manufacturing practice compliance), cost of capital and access to testing facilities.
“The challenge is upstream.”
What to Watch
What to watch: progress of API parks, quality-enforcement actions, and the shift toward complex generics and biosimilars.
More pieces to commission: medical devices in Himachal and Gujarat; hospital chains outside metros; diagnostics MSMEs; digital health under the ABDM.
- [VERIFY: pharma exports reported at above $28 billion; source from the Pharmexcil/commerce ministry release.]
- More pieces to commission: medical devices in Himachal and Gujarat; hospital chains outside metros; diagnostics MSMEs; digital health under the ABDM.
The Editorial Desk
Perspectives on the people, ideas and businesses shaping what comes next. The articles in this preview are illustrative samples, not reported journalism.
More from the Editorial Desk
